OliX Pharmaceuticals, Inc. Logo

OliX Pharmaceuticals, Inc.

Developing RNAi therapeutics for dermatology, ophthalmology, and metabolic diseases via an asiRNA platform.

226950 | KO

Overview

Corporate Details

ISIN(s):
KR7226950004
LEI:
Country:
South Korea
Address:
경기도 성남시 수정구 고등동 608-3 -, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

OliX Pharmaceuticals, Inc. is a clinical-stage biotechnology company that specializes in the development of novel therapeutics based on RNA interference (RNAi) technology. The company leverages its proprietary asymmetric small interfering RNA (asiRNA) platform to discover and advance next-generation nucleic acid-based treatments. Its development pipeline is focused on addressing diseases with high unmet medical needs, particularly in dermatology, ophthalmology, and metabolic disorders. Key programs in its pipeline target conditions such as hypertrophic scars, androgenetic alopecia (male-pattern baldness), age-related macular degeneration (AMD), and metabolic dysfunction-associated steatohepatitis (MASH). OliX aims to develop locally administrable therapies to improve safety and efficacy, positioning itself as an innovator in oligonucleotide therapeutics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-09-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-09-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 146.9 KB
2025-08-28 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.7 KB
2025-08-26 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 14.3 KB
2025-08-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-19 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 164.1 KB
2025-08-19 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 125.8 KB
2025-08-19 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-08-14 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 22.2 KB
2025-08-14 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 23.7 KB
2025-08-14 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 22.7 KB
2025-08-14 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 22.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.7 MB

Automate Your Workflow. Get a real-time feed of all OliX Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for OliX Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for OliX Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Gencurix Inc. Logo
Develops molecular diagnostic tests for cancer detection, prognosis, and treatment selection.
South Korea
229000
GENELUX Corp Logo
Developing oncolytic viral immunotherapies for difficult-to-treat cancers using a vaccinia virus.
United States of America
GNLX
GENEMATRIX INC. Logo
Develops multiplex PCR diagnostics and new drugs for infectious diseases like HPV and tuberculosis.
South Korea
109820
Genenta Science S.p.A. Logo
Develops cell & gene therapies using engineered stem cells to treat solid tumors.
United States of America
GNTA
GeneOne Life Science, Inc. Logo
Develops nucleic acid vaccines & therapies for infectious diseases, cancer & autoimmune disorders.
South Korea
011000
Generation Bio Co. Logo
Developing siRNA genetic medicines via targeted nanoparticles for autoimmune diseases.
United States of America
GBIO
Genetic Analysis AS Logo
Develops microbiome diagnostics to detect gut dysbiosis for clinical and pharma partners.
Norway
GEAN
GENFIT Logo
Biopharma developing therapies & diagnostics for rare, life-threatening liver diseases.
France
GNFT
Genfit S.A. Logo
Biopharma developing therapeutics and diagnostics for rare and life-threatening liver diseases.
United States of America
GNFT
GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. Logo
Develops and manufactures pharmaceuticals for rare diseases and unmet health needs globally.
Türkiye
GENIL

Talk to a Data Expert

Have a question? We'll get back to you promptly.